AMENDED CLAIMS

received by the International Bureau on 24 May 2016(24.05.2016)

i WE CLAIM

1. A compound of general formula 1

N^N

General formula 1

wherein substituent 'Si' is selected from one of the formula la

^R1 v N ^R2 j Hetero;

' k -Ar

1a 1b

and substituent 'S₂' is represented by formula lc

1c

wherein 'X' is independently selected from any of NR₃, O, CH₂,

'Ri, R_2, are independently selected from any of un/substituted alkyl Ci-C₁₄, un/substituted acyl C₂ to C₁₄, un/substituted phenyl ring and further substitution contains any of the following atoms or groups such as F, CI, Br, I, CN, NR₄R₅, CF₃, CHCF₂, CH₂F, OCF₃, OCH₂CF₃, OR₆, N0₂, NO, CHR₇R₈, alkyl chain from d to C_M, COOR₉, CHO, COR10, COCF₃, COCH₂CF₃, SR_n, SOR_i2, S0₂R_i3, SONR14R15, S0₂NR_MRi7, cycloalkyl etc either mono or di or poly at any of the available position,

R₃ is independently selected from any of H, un/substituted alkyl C₁-C₁₄, un/substituted acyl C₂ to C₁₄, un/substituted phenyl ring and further substitution contains any of the following atoms or groups such as F, CI, Br, I, CN, NR₄R₅, CF₃, CHCF₂, CH₂F, OCF₃, 52

OCH₂CF₃, OR₆, N0₂, NO, CHR₇R₈, alkyl chain from d to C_M, COOR₉, CHO, COR₁₀, COCF3, COCH2CF3, SR11, SOR12, SO2R13, SONR14R15, S0₂NRi₄Ri₇, cycloalkyl etc either mono or di or poly at any of the available position,

ίΊ-leteroi

k -Ar )

I is independently selected from any of following un/substituted N-heterocyles such as indolyl, triazolyl, pyrrolyl, imidazoyl, benzotriazolyl, benzoimidazolyl, thiazoyl etc attached though N— atom or through any of the available ring position and further substituted heterocycles contains any of the following atom or group such as F, CI, Br, I, CN, NR4R5, CF₃, CHF₂, CH₂F, OCF₃, OCH₂CF₃, OR₆, N0₂, NO, CHR₇R₈, alkyl chain from Ci to C_M, COOR₉, CHO, COR10, COCF₃, COCH₂CF₃, SRn, SOR12, SO2R13, SONR14R15, S0₂NRi₄Ri₇, cycloalkyl,

'Ar' is independently selected from any of un/substituted phenyl, un/ substituted napthyl and attached through any of the available ring position and further substitution selected from any of the following atom or group such as F, CI, Br, I, CN, NR₄R₅, CF₃, CHCF₂, CH₂F, OCF₃, OCH₂CF₃, OR₆, N0₂, NO, CHR₇R₈, alkyl chain from Ci to C_M, COOR9, CHO, COR10, COCF3, COCH2CF3, SRn, SOR12, SO2R13, SONR14R15, S0₂NRi₄Ri₇, cycloalkyl,

'Hetero-Ar' is independently selected from any of un/substituted hetrocycles such as pyridyl, triazolyl, triazinyl, pyrimidinyl, pyridazinyl, oxazolyl, furanyl, benzofuranyl, thiophenyl, pyrrolyl, imidazoyl, thiazoyl, quinolinyl, isoquinolinyl, benzooxazolyl, and benzothiazolyl, indolyl, benzotriazolyl, benzoimidazolyl etc and attached through any of the available ring position and further substituted heterocycles contains any of the following atom or group such as F, CI, Br, I, CN, NR₄R₅, CF₃, CHCF₂, CH₂F, OCF₃, OCH2CF3, OR₆, N0₂, NO, CHR₇R₈, alkyl chain from Ci to C_M, COOR₉, CHO, COR10, COCF3, COCH2CF3, SRn, SOR12, SO2R13, SONR14R15, S0₂NRi₄Ri₇, cycloalkyl, R4, R₅, R₆, R₇, R₈, R₉, Rio, Rn, R12, R13, Ri4, R15, Ri4 and R_i7' are independently selected from any of following substitution such as H, linear alkyl chain C1-C10, branched alkyl chain C3-C10, un/substituted phenyl ring.

2. The compound of general formula 1, as claimed in claim 1 , comprises of group with formula 1A and formula IB,

r'

! Hetero-I

N^ N N^N

1A ' 1 B \

Ar/ - ' AT/ >

Ί Hetero-Ar-' - Hetero-An

\ -- ---

'X' is independently selected from any of NR₃, O, CH₂,

'Ri, R₂' are independently selected from any of following atom or groups un/substituted alkyl C1-C14, un/substituted acyl C₂ to C₁₄, un/substituted phenyl ring, un/substituted heterocycles and further substitution contains any of the following atoms or groups such as F, CI, Br, I, CN, NR4R5, CF₃, CHCF₂, CH₂F, OCF₃, OCH₂CF₃, OR₆, N0₂, NO, CHR₇R₈, alkyl chain from d to C_M, COOR₉, CHO, COR10, COCF_3, COCH₂CF₃, SR11, SORi₂, S0₂R_i3, SONR14R15, S0₂NR_MRi₇, cycloalkyl either mono or di or poly substituted at any of the available position,

R₃ is independently selected from any of H, un/substituted alkyl C1-C14, un/substituted acyl C₂ to C₁₄, un/substituted phenyl ring and further substitution contains any of the following atoms or groups such as F, CI, Br, I, CN, NR4R5, CF₃, CHCF₂, CH₂F, OCF₃, OCH₂CF₃, OR₆, N0₂, NO, CHR₇R₈, alkyl chain from Ci to C_M, COOR9, CHO, COR10, COCF₃, COCH₂CF₃, SR11, SOR_i2, S0₂R_i3, SONR14R15, S0₂NR_MRi₇, cycloalkyl either mono or di or poly at any of the available position, [Ί-leteroj

k -Ar j

5 I is independently selected from any of following un/substituted N-heterocyles such as indolyl, triazolyl, pyrrolyl, imidazoyl, benzotriazolyl, benzoimidazolyl, thiazoyl attached though N— atom or any of the available ring position and further substituted heterocycles contains any of the following atom or group such as F, CI, Br, I, CN, NR₄R₅, CF₃, CHF₂, CH₂F, OCF₃, OCH₂CF₃, OR₆, N0₂, NO, CHR₇R₈, alkyl 10 chain from Ci to C_M, COOR₉, CHO, COR₁₀, COCF_3, COCH₂CF₃, SRn, SOR_i2, S0₂Ri3, SONR14R15, S0₂NR_MRi₇, cycloalkyl,

'Ar' is independently selected from any of un/substituted phenyl, un/ substituted naphthyl and attached through any of the available ring position and further substitution selected from any of the following atom or group such as F, CI, Br, I, CN, 15 NR₄R₅, CF₃, CHCF₂, CH₂F, OCF₃, OCH₂CF₃, OR₆, N0₂, NO, CHR₇R₈, alkyl chain from Ci to C_M, COOR₉, CHO, COR₁₀, COCF_3, COCH₂CF₃, SRn, SOR_i2, S0₂Ri₃, SONR14R15, S0₂NR_MRi₇, cycloalkyl,

'Hetero-Ar' is independently selected from any of un/substituted hetrocycles such as pyridyl, triazolyl, triazinyl, pyrimidinyl, pyridazinyl, oxazolyl, furanyl, benzofuranyl,

20 thiophenyl, pyrrolyl, imidazoyl, thiazoyl, quinolinyl, isoquinolinyl, benzooxazolyl, and benzothiazolyl, indolyl, benzotriazolyl, benzoimidazolyl etc and attached through any of the available ring position and further substituted heterocycles contains any of the following atom or group such as F, CI, Br, I, CN, NR₄R₅, CF₃, CHCF₂, CH₂F, OCF₃, OCH₂CF₃, OR₆, N0₂, NO, CHR₇R₈, alkyl chain from Ci to C_M, COOR₉, CHO,

25 COR₁₀, COCF_3, COCH₂CF₃, SRn, SOR_i2, S0₂Ri₃, SONR₁₄R₁₅, S0₂NRi₄Ri₇, cycloalkyl,

R4, R₅, R₆, R₇, R₈, R9, Rio, R11, Ri₂, Ri₃, Ri4, R15, Ri4 and R_i7' are independently selected from any of following substitution such as H, linear alkyl chain C₁-C₁₀, branched alkyl chain C₃-Cio, un/substituted phenyl ring.

303. The compound of general formula 1 as claimed in claim 1, wherein representative compounds of formula 1A and IB, comprising: 55

4-(4-(4-fluorophenoxy)piperidin- 1 -yl)-N-methyl-6-morpholino-N-phenyl- 1 ,3 ,5-triazin- 2-amine (compound 1A1 , Table 1)

4-(4-(2-fluorophenoxy)piperidin- 1 -yl)-N-methyl-6-morpholino-N-phenyl- 1 ,3 ,5-triazin- 2-amine (compound 1A2, Table 1)

4-(4-(4-fluorophenoxy)piperidin- l -yl)-N-(4-fluorophenyl)-N-methyl-6-morpholino- l ,3,5-triazin-2-amine (compound 1A3, Table 1)

2,2,2-trifluoro-N-(4-morpholino-6-(4-phenoxypiperidin- l-yl)- l ,3,5-triazin-2-yl)-N- phenylacetamide (compound 1A4, Table 1)

2,2,2-trifluoro-N-(4-fluorophenyl)-N-(4-morpholino-6-(4-phenoxypiperidin- l-yl)- l ,3,5-triazin-2-yl)acetamide (compound 1A5, Table 1 )

2,2,2-trifluoro-N-(4-(4-(4-fluorophenoxy)piperidin- l-yl)-6-morpholino- l ,3,5-triazin-2- yl)-N-(4-fluoro phenyl)acetamide (compound 1A6, Table 1)

2,2,2-trifluoro-N-(4-morpholino-6-(4-(4-(trifluoromethyl)phenoxy)piperidin- l-yl)- l ,3,5-triazin-2-yl)-N-phenylacetamide(compound 1A7, Table 1)

2,2,2-trifluoro-N-(4-morpholino-6-(4-(p-tolyloxy)piperidin- l-yl)- l ,3,5-triazin-2-yl)-N- phenylacetamide (compound 1A8, Table 1)

2,2,2-trifluoro-N-(4-morpholino-6-(4-(4-(trifluoromethoxy)phenoxy)piperidin- l-yl)- l ,3,5-triazin-2-yl)-N-phenylacetamide (compound 1A9, Table 1)

2,2,2-trifluoro-N-(4-morpholino-6-(4-(2-(trifluoromethyl)phenoxy)piperidin- l-yl)- l ,3,5-triazin-2-yl)-N-phenylacetamide(compound 1A10, Table 1)

2,2,2-trifluoro-N-methyl-N-(4-morpholino-6-(4-phenoxypiperidin- l-yl)- l ,3,5-triazin- 2-yl)acetamide (compound 1A1 1 , Table 2)

2,2,2-trifluoro-N-(4-morpholino-6-(4-phenoxypiperidin- l-yl)- l ,3,5-triazin-2-yl)-N- (2,2,2-trifluoro acetyl)acetamide (compound 1A12, Table 2)

2,2,2-trifluoro-N-(4-(4-(4-fluorophenoxy)piperidin- l-yl)-6-morpholino- l ,3,5-triazin-2- yl)-N-(2,2,2-trifluoroacetyl)acetamide (compound 1A13, Table 2)

2,2,2-trifluoro-N-(4-(4-(2-fluorophenoxy)piperidin- l-yl)-6-morpholino- l ,3,5-triazin-2- yl)-N-(2,2,2-trifluoroacetyl)acetamide (compound 1A14, Table 2) 56

2,2,2-trifluoro-N-(4-(4-(4-fluorophenoxy)piperidin-l-yl)-6-morpholino-l ,3,5-triazin-2- yl)-N-methyl acetamide (compound 1A15, Table 2)

N,N-dimethyl-4-morpholino-6-(4-(p-tolyloxy)piperidin-l-yl)- l,3,5-triazin-2-amine (compound 1A16, Table 2)

4-(4-(4-fluorophenoxy)piperidin- 1 -yl)-NN-dimethyl-6-morpholino- 1 ,3 ,5-triazin-2- amine (compound 1A12, Table 2) (compound 1A17, Table 2)

4-morpholino-6-(4-phenoxypiperidin- 1 -yl)-NN-diphenyl- 1 ,3,5-triazin-2-amine (compo

und 1A18, Table 2)

4-morpholino-N,N-diphenyl-6-(4-(2-(trifluoromethyl)phenoxy)piperidin-l-yl)- 1,3,5- triazin-2-amine (compound 1A19, Table 2)

4-morpholino-N,N-diphenyl-6-(4-(4-(trifluoromethoxy)phenoxy)piperidin- 1 -yl)- 1,3,5- triazin-2-amine (compound 1A20, Table 2

4-(4-(2-(difluoromethyl)- lH-benzo[JJimidazol -l-yl)-6-(4-(4- fluorophenoxy)piperidin-l-yl)-l,3,5-triazin-2-yl)morpholine (compound 1B 1, Table 3) 4-(4-(2-(difluoromethyl)- lH-benzo[JJimidazol -l-yl)-6-(4-(4- methoxyphenoxy)piperidin-l-yl)-l ,3,5-triazin-2-yl)morpholine (compound 1B2, Table 3)

4-(4-(2-(difluoromethyl)- lH-benzo[JJimidazol -l-yl)-6-(4-(4-

(trifluoromethoxy)phenoxy)piperidin-l-yl)-l ,3,5-triazin-2-yl)morpholine (compound 1B3, Table 3)

4-(4-(2-(difluoromethyl)- lH-benzo[JJimidazol -l-yl)-6-(4-(2-

(trifluoromethyl)phenoxy)piperidin-l-yl)-l ,3,5-triazin-2-yl)morpholine (compound 1B4, Table 3)

4-(4-(4-(4-chlorophenoxy)piperidin- 1 -yl)-6-(2-(difluoromethyl)- lH-benzo[JJimidazol- l-yl)-l,3,5-triazin-2-yl)morpholine (compound 1B5, Table 3)

4-(4-(4-(3-chlorophenoxy)piperidin- 1 -yl)-6-(2-(difluoromethyl)- lH-benzo[JJimidazol -l-yl)-l,3,5-triazin-2-yl)morpholine (compound 1B6, Table 3) 57

4-(4-(4-(2-chlorophenoxy)piperidin- 1 -yl)-6-(2-(difluoromethyl)- lH-benzo[JJimidazol -l-yl)-l,3,5-triazin-2-yl)morpholine (compound 1B7, Table 3)

4-(4-(2-(difluoromethyl)- lH-benzo[JJimidazol -l-yl)-6-(4-(3- fluorophenoxy)piperidin-l-yl)-l,3,5-triazin-2-yl)morpholine (compound 1B8, Table 3) 4-(4-(2-(difluoromethyl)- lH-benzo[JJimidazol -l-yl)-6-(4-(2- fluorophenoxy)piperidin-l-yl)-l,3,5-triazin-2-yl)morpholine (compound 1B9, Table 3) 4-(4-(2-(difluoromethyl)- lH-benzo[JJimidazol -l-yl)-6-(4-(p-tolyloxy)piperidin-l- yl)-l,3,5-triazin-2-yl)morpholine (compound IB 10, Table 3)

4-(4-(2-(difluoromethyl)- lH-benzo[JJimidazol -l-yl)-6-(4-(m-tolyloxy)piperidin-l- yl)-l,3,5-triazin-2-yl)morpholine (compound 1B11, Table 4)

4-(4-(2-(difluoromethyl)- lH-benzo[JJimidazol -l-yl)-6-(4-(o-tolyloxy)piperidin-l- yl)-l,3,5-triazin-2-yl)morpholine (compound IB 12, Table 4)

4-(4-(5-fluoro- lH-benzo[JJimidazol- 1 -yl)-6-(4-(p-tolyloxy)piperidin- 1 -yl)- 1,3,5- triazin-2-yl)morpholine (compound IB 13, Table 4)

4-(4-(5-fluoro-lH-benzo[JJimidazol -l-yl)-6-(4-(4- (trifluoromethyl)phenoxy)piperidin-l-yl)-l,3,5-triazin-2-yl)morpholine (compound IB 14, Table 4)

4-(4-(lH-benzo[JJimidazol -l-yl)-6-(4-(4-(trifluoromethyl)phenoxy)piperidin-l-yl)- l,3,5-triazin-2-yl)morpholine (compound 1B15, Table 4)

4-(4-(lH-benzo[JJimidazol -l-yl)-6-(4-(4-(trifluoromethoxy)phenoxy)piperidin-l-yl)- l,3,5-triazin-2-yl)morpholine (compound 1B16, Table 4)

4-(4-( 1 H-benzo[JJ imidazol- 1 -yl)-6-(4-(4-fluorophenoxy)piperidin- 1 -yl)- 1 , 3 ,5 -triazin- 2-yl)morpholine (compound IB 17, Table 4)

4-(4-( 1 H-benzo[JJ imidazol- 1 -yl)-6-(4-(2-fluorophenoxy)piperidin- 1 -yl)- 1 , 3 ,5 -triazin- 2-yl)morpholine (compound IB 18, Table 4)

4-(4-( lH-benzo[JJ imidazol- l-yl)-6-(4-(2-chlorophenoxy)piperidin- 1 -yl)- 1 ,3,5-triazin- 2-yl)morpholine (compound IB 19, Table 4)

4-(4-(lH-benzo[JJimidazol -l-yl)-6-(4-(2-(trifluoromethyl)phenoxy)piperidin-l-yl)- l,3,5-triazin-2-yl)morpholine (compound 1B20, Table 4) 58

l-(4-(2-(difluoromethyl)- lH-benzo[JJimidazol -l-yl)-6-morpholino-l,3,5-triazin-2- yl)-N-(4-fluoro phenyl)piperidin-4-amine (compound 1B21 , Table 5)

l-(4-(2-(difluoromethyl)- lH-benzo[JJimidazol -l-yl)-6-morpholino-l,3,5-triazin-2- yl)-N-(4-(trifluoro methyl)phenyl)piperidin-4-amine (compound 1B22, Table 5) l-(4-(2-(difluoromethyl)- lH-benzo[JJimidazol -l-yl)-6-morpholino-l,3,5-triazin-2- yl)-N-(4-(trifluoro methoxy)phenyl)piperidin-4-amine (compound 1B23, Table 5) l-(4-(2-(difluoromethyl)- lH-benzo[JJimidazol-l-yl)-6-morpholino-l,3,5-triazin-2- yl)-N-(4-methoxy phenyl)piperidin-4-amine (compound 1B24, Table 5)

N-(4-bromophenyl)- 1 -(4-(2-(difluoromethyl)- lH-benzo[JJimidazol- 1 -yl)-6- morpholino-l,3,5-triazin-2-yl)piperidin-4-amine (compound 1B25, Table 5)

N-(3 ,4-dichlorophenyl)- 1 -(4-(2-(difluoromethyl)- lH-benzo[JJimidazol - 1 -yl)-6- morpholino-l,3,5-triazin-2-yl)piperidin-4-amine (compound 1B26, Table 5) l-(4-(2-(difluoromethyl)- lH-benzo[JJimidazol-l-yl)-6-morpholino-l,3,5-triazin-2- yl)-N-(2-fluoro phenyl)piperidin-4-amine (compound 1B27, Table 5)

l-(4-(2-(difluoromethyl)- lH-benzo[JJimidazol -l-yl)-6-morpholino-l,3,5-triazin-2- yl)-N-(2-methoxy phenyl)piperidin-4-amine (compound 1B28, Table 5)

l-(4-(2-(difluoromethyl)- lH-benzo[JJimidazol-l-yl)-6-morpholino-l,3,5-triazin-2- yl)-N-(2-(trifluoro methyl)phenyl)piperidin-4-amine (compound 1B29, Table 5) l-(4-(2-(difluoromethyl)- lH-benzo[JJimidazol -l-yl)-6-morpholino-l,3,5-triazin-2- yl)-N-(p-tolyl) piperidin-4-amine (compound 1B30, Table 5)

l-(4-(2-(difluoromethyl)- lH-benzo[JJimidazol -l-yl)-6-morpholino-l,3,5-triazin-2- yl)-N-(3-methoxy phenyl)piperidin-4-amine (compound 1B31 , Table 5)

l-(4-(2-(difluoromethyl)- lH-benzo[JJimidazol -l-yl)-6-morpholino-l,3,5-triazin-2- yl)-N-(o-tolyl) piperidin-4-amine (compound 1B32, Table 6)

1 -(4-(2-(difluoromethyl)-5-fluoro- lH-benzo[JJimidazol - 1 -yl)-6-morpholino- 1,3,5- triazin-2-yl)-N-(p-tolyl)piperidin-4-amine (compound 1B33, Table 6)

1 -(4-(2-(difluoromethyl)-5-fluoro- lH-benzo[JJimidazol - 1 -yl)-6-morpholino- 1,3,5- triazin-2-yl)-N-(4-(trifluoromethyl)phenyl)piperidin-4-amine (compound 1B34, Table

6) 59

l-(4-(2-(difluoromethyl)- lH-benzo[JJimidazol-l-yl)-6-morpholino-l,3,5-triazin-2- yl)-N-(4-(trifluoro methyl)phenyl)piperidin-4-amine (compound 1B35, Table 6) l-(4-(2-(difluoromethyl)- lH-benzo[JJimidazol-l-yl)-6-morpholino-l,3,5-triazin-2- yl)-N-(4-(trifluoro methoxy)phenyl)piperidin-4-amine (compound 1B36, Table 6) l-(4-(2-(difluoromethyl)- lH-benzo[JJimidazol -l-yl)-6-morpholino-l,3,5-triazin-2- yl)-N-(4-fluoro phenyl )piperidin-4-amine (compound 1B37, Table 6)

l-(4-(2-(difluoromethyl)- lH-benzo[JJimidazol -l-yl)-6-morpholino-l,3,5-triazin-2- yl)-N-(2-fluoro phenyl)piperidin-4-amine (compound 1B38, Table 6)

N-(2-chlorophenyl)- 1 -(4-(2-(difluoromethyl)- lH-benzo[JJimidazol-l-yl)-6- morpholino-l,3,5-triazin-2-yl)piperidin-4-amine (compound 1B39, Table 6) l-(4-(2-(difluoromethyl)- lH-benzo[JJimidazol-l-yl)-6-morpholino-l,3,5-triazin-2- yl)-N-(2-(trifluoro methyl)phenyl)piperidin-4-amine (compound 1B40, Table 6) l-(4-(2-(difluoromethyl)- lH-benzo[JJimidazol -l-yl)-6-morpholino-l,3,5-triazin-2- yl)-N,N-bis(4-fluorophenyl)piperidin-4-amine (compound 1B41, Table 7)

N-(4-bromophenyl)- 1 -(4-(2-(difluoromethyl)- lH-benzo[JJimidazol- 1 -yl)-6- morpholino-l,3,5-triazin-2-yl)-N-(4-fluorophenyl)piperidin-4-amine (compound 1B42, Table 7)

1- (4-(2-(difluoromethyl)- lH-benzo[J]imidazol-l-yl)-6-morpholino-l,3,5-triazin-2-yl)- N-(4-fluorophenyl)-N-(4-(trifluoromethyl)phenyl)piperidin-4-amine(compound 1B43, Table 7)

N-(4-chlorophenyl)- 1 -(4-(2-(difluoromethyl)- lH-benzo[JJimidazol-l-yl)-6- morpholino-l,3,5-triazin-2-yl)-N-(4-fluorophenyl)piperidin-4-amine (compound 1B44, Table 7)

N-( 1 -(4-(2-(difluoromethyl)- lH-benzo[JJimidazol - 1 -yl)-6-morpholino- 1 ,3,5-triazin-

2- yl) piperidin-4-yl)-N-(4-fluorophenyl)-3-(trifluoromethyl)pyridin-4- amine(compoundlB45, Table 7)

l-(4-(2-(difluoromethyl)- lH-indol-l-yl)-6-morpholino-l,3,5-triazin-2-yl)-N-(4-fluoro phenyl)piperidin-4-amine (compound 1B46, Table 7) 60

l-(4-(2-(difluoromethyl)- lH-indol- l-yl)-6-morpholino- l ,3,5-triazin-2-yl)-N-(4- methoxy phenyl)piperidin-4-amine (compound 1B47, Table 7)

l-(4-(2-(difluoromethyl)- lH-indol- l-yl)-6-morpholino- l ,3,5-triazin-2-yl)-N-(4- (trifluoro methoxy)phenyl)piperidin-4-amine (compound 1B48, Table 7)

1- (4-(2-(difluoromethyl)- lH-indol- l-yl)-6-morpholino- l ,3,5-triazin-2-yl)-N-(4- (trifluoro methyl )phenyl)piperidin-4-amine (compound 1B49, Table 7)

N-(4-chlorophenyl)- 1 -(4-(2-(difluoromethyl)- lH-indol- l-yl)-6-morpholino- 1 ,3,5- triazin-2-yl)piperidin-4-amine (compound 1B50, Table 7)

4. Use of the compound of formula I as claimed in claim 1 as P13K inhibitors.

5. Use of the compound of general formula I as claimed in claim 1 as anti-cancer agents.

6. A process for the preparation of the compound of general formula 1 as claimed in claim 1 wherein the process steps comprising;

(i) reacting disubstituted triazine compound of formula 5, wherein Gi is selected from a group consisting of Ph, (4-F)-Ph, CH₃, COCF₃ and G₂ is selected from a group consisting of CH₃, COCF₃ and Ph or 8, wherein FGi is selected from a group consisting of H or F and FG₂ is selected from a group consisting 2-CHF₂ or H with aryloxy piperidines 6, wherein FG₃ is selected from a group consisting of 4-F, 4-OMe,

2- CF₃, 4-Cl, 3-Cl, 2-Cl, 4-CN, 2-CN, 4-CH₃, 3-CH₃, 2-CH₃, 4-CF₃, 4-OCF₃, 4-F, 2-F, 4-Cl, 2-CF₃ or piperidones 9 in an organic solvent selected from a group consisting of DMF, THF, CH₃CN (added) in the presence of alkali metal carbonate selected from a group consisting of K₂C0₃, Na₂C0₃, Cs₂C0₃(added) at a temperature ranging between 10 °C to 80 °C for a period ranging between 1 to 24 hrs, to obtain compound of formula 1Α( 1 -20), wherein Gi is selected from a group consisting Ph, (4-F)-Ph, CH₃, COCF₃ and G₂ is selected from a group consisting of CH₃, COCF₃ and FG is selected from a group consisting of 4-F, 2-F, H, 4-CF₃, 4-CH₃, 4-OCF₃ or 1Β( 1 -20), wherein FGi is selected from a group consisting H, 5-F, and FG₂ is selected from the group consisting of 2-CHF₂ and FG₃ is selected from the group consisting of 4-F, 4- OMe, 4-OCF₃, 2-CF₃3-Cl, 2-Cl, 4-CN, 2-CN, 4-CH₃, 3-CH₃, 2-CH₃, 4-OCF₃, 4-F, 2-F, 61

4-Cl, 2-CF₃ or trisubstituted triazine compound 10, wherein FGi selected from a group consisting of H or 5-F and FG₂ selected from a group consisting H or 2-CHF₂ and 15,

(ii) reacting trisubstituted triazine compound 10, wherein FGi is selected from a group consisting of H or 5-F or wherein FG₂ is selected from a group consisting of 2-CHF₂ or 15, wherein FG₂ is selected from a group consisting of 2-CHF₂ or H with substituted aryl amine of formula 11, wherein FG₄ is selected from a group consisting of 4F, 4- CF₃, 4-OCH₃, 4-Br, 3, 4 DiCl, 2-F, 2-OCH₃, 2-CF₃, 3-OCH₃, 2-CH₃, 4-CH₃(added) in an organic solvent selected from a group consisting of DCM, DCE, THF, MeOH (added ) in presence of acetic acid and a reducing agent selected from a group consisting of sodium triacetoxy borohydride, sodium borohydride (added) at a temperature ranging between 10 °C to 80 °C for a period renging between 1 to 24 hrs, to obtain compound IB (21-40), wherein FGi is selected from the group consisting of H or 5-F, FG₂ is selected from the group consisting of 2-CHF₂ and H, and FG₄ is selected from the group consisting 4F, 4-CF₃, 4-OCH₃, 4-Br, 3, 4 DiCl, 2-F, 2-OCH₃, 2-CF₃, 3-OCH₃, 2-CH₃, 4-CH₃of or IB (46-50), wherein FGi is selected from the group consisting of H or 5-F, FG₂ is selected from the group consisting of 2-CHF₂ and H, and FG₄ is selected from the group consisting of 4-F, 4-OMe, 4-OCF_3i 4-CF₃, 4-Cl respectively,

(iii) reacting trisubstituted triazine compound 1B21 with substituted aryl boronic acid of formula 12, wherein FG5 is selected from a group consisting of halogen or CF₃, in an organic solvent selected from a group consisting of DCM, DCE, MeOH, CH₃CN (added) in presence of triethylamine and copper acetate at a temperature ranging between 10 °C to 80 °C for a period in the range of 1 to 24 hrs, to obtain compound of formula 1Β(41-45), wherein FG₅ is selected from the group consisting of 4-F, 4-Br, 4- CF₃ 4-Cl and 2-CF₃ and Y is selected from the group consisting of CH or N"

7. The process as claimed in claim 6, wherein aryloxy piperidines is selected from the group consisting of 4-(4-fluorophenoxy)piperidine, 4-(4-methoxyphenoxy)piperidine, 4-(4-(trifluoromethoxy) phenoxy) piperidine, 4-(2- 62

(trifluoromethyl)phenoxy)piperidine, 4-(4-chlorophenoxy)piperidine, 4-(3-chloro phenoxy)piperidine, 4-(2-chlorophenoxy)piperidine, 4-(p-tolyloxy)piperidine, 4-(m- tolyloxy)

piperidine, 4-(o-tolyloxy)piperidine, 4-(4-(trifluoromethyl)phenoxy)piperidine, 4- (piperidin-4-yloxy)benzonitrile, 2-(piperidin-4-yloxy)benzonitril, 4-(2- fluorophenoxy)piperidine .

8. The process as claimed in claim 6, wherein substituted aryl amine is selected from the group consisting of 4-Fluoro aniline, 4-Trifluoromethyl aniline, 4-Trifluoromethoxy aniline 4-Methoxy aniline, 4-Bromo aniline, 3, 4-Dichloro aniline, 2-Fluoro aniline,

2- Methoxy aniline, 2-Trifluoromethyl aniline , 3-Methoxy aniline, 2-Methyl aniline,

3- Methyl aniline, 4-Methyl aniline.